Advertisement

Angiotensin II in septic shock

Published:March 19, 2019DOI:https://doi.org/10.1016/j.ajem.2019.03.026

      Abstract

      Septic shock is a life threatening condition and a medical emergency. It is associated with organ dysfunction and hypotension despite optimal volume resuscitation. Refractory septic shock carries a very high rate of mortality and is associated with ischemic and arrhythmogenic complications from high dose vasopressors. Angiotensin II (AT-II) is a product of the renin-angiotensin-aldosterone system. It is a vasopressor agent that has been recently approved by FDA to be used in conjunction with other vasopressors (catecholamines) in refractory shock and to reduce catecholamine requirements. We have reviewed the physiology and current literature on AT-II in refractory septic/vasodilatory shock. Larger trials with longer duration of follow-up are warranted to address the questions which are unanswered by the ATHOS-3 trial, especially pertaining to its effects on lungs, brain, microcirculation, inflammation, and venous thromboembolism risk.

      Keywords

      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Singer M.
        • Deutschman C.S.
        • Seymour C.W.
        • et al.
        The third international consensus definitions for sepsis and septic shock (sepsis-3).
        JAMA. 2016; 315: 801-810https://doi.org/10.1001/jama.2016.0287
        • Shankar-Hari M.
        • Phillips G.S.
        • Levy M.
        • et al.
        Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3).
        JAMA. 2016; 315: 775-787
        • Seymour C.W.
        • Liu V.X.
        • Iwashyna T.J.
        • et al.
        Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3).
        JAMA. 2016; 315: 762-774https://doi.org/10.1001/jama.2016.0288
        • Antonucci E.
        • Fiaccadori E.
        • Donadello K.
        • et al.
        Myocardial depression in sepsis: from pathogenisis to clinical manifestations and treatment.
        J Crit Care. 2014; 29: 500-511https://doi.org/10.1016/j.jcrc.2014.03.028
        • Dellinger R.P.
        • Levy M.M.
        • Rhodes A.
        • et al.
        Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock.
        Crit Care Med. 2012; 41: 580-637https://doi.org/10.1097/CCM.0b013e31827e83af
        • Asfar P.
        • Meziani F.
        • Hamel J.F.
        • et al.
        High vs low blood pressure target in patients with septic shock.
        N Engl J Med. 2014; 370: 1583-1593
      1. Lavrentyev EN, Estes AM, Malik KU et al. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 2007; 101:455–464. [PubMed: 17626897].

        • Kumar R.
        • Boim M.A.
        • et al.
        Diversity of pathways for intracellular angiotensin II synthesis.
        Curr Opin Nephrol Hypertens. 2009; 18 ([PubMed: 19077687]): 33-39
        • Kumar R.
        • Thomas C.M.
        • Yong Q.C.
        • et al.
        The intracrine rennin angiotensin system.
        Clin. Sci. (Lond.). 2012; 123: 273-284
        • Paul M.
        • Poyan Mehr A.
        • Kreutz R.
        • et al.
        Physiology of local renin-angiotensin systems.
        Physiol Rev. 2006; 86: 747-803
        • Correˆa T.D.
        • Takala J.
        • Jakob S.M.
        • et al.
        Angiotensin II in septic shock.
        Crit Care. 2015; 16: 98
        • Donoghue M.
        • Hsieh F.
        • Baronas E.
        • et al.
        A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9.
        Circ Res. 2000; 87: e1-e9https://doi.org/10.1161/01.RES.87.5.e1
        • Santos R.A.
        • Ferreira A.J.
        Angiotensin-(1–7) and the renin-angiotensin system.
        Curr Opin Nephrol Hypertens. 2007; 16: 122-128
        • McKinney C.A.
        • Kennedy S.
        • Ballie G.
        • et al.
        178 Angiotensin 1-9 inhibits vascular smooth muscle cell proliferation and migration in vitro and neointimal formation in vivo.
        Heart. 2015; 101: A101
        • Fyhrquist F.
        • Saijonmaa O.
        • et al.
        Renin-angiotensin system revisited.
        J Intern Med. 2008; 264: 224-236https://doi.org/10.1111/j.1365-2796.2008.01981.x
        • Zhuo J.L.
        • Li X.C.
        • et al.
        New insights and perspectives on intrarenal rennin angiotensin system: focus on intracrine/intracellular angiotensin II.
        Peptides. 2011; 32: 1551-1565https://doi.org/10.1016/j.peptides.2011.05.012
        • Bodor C.
        • Nagy J.
        • Végh B.
        • et al.
        Angiotensin II increases the permeability and PV-1 expression of endothelial cells.
        Am J Physiol Cell Physiol. 2012; 302: C267-C276https://doi.org/10.1152/ajpcell.00138.2011
        • Tamion F.
        • Le Cam-Duchez V.
        • Menard J.F.
        • et al.
        Erythropoietin and renin as biological markers in critically ill patients.
        Crit Care. 2004; 8: R328-R335https://doi.org/10.1186/cc2902
        • Doerschug K.C.
        • Delsing A.S.
        • Schmidt G.A.
        • et al.
        Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis.
        Crit Care. 2010; 14: R24https://doi.org/10.1186/cc8887
        • Hilgenfeldt U.
        • Kienapfel G.
        • Kellermann W.
        • et al.
        Renin angiotensin system in sepsis.
        Clin Exp Hypertens A. 1987; 9: 1493-1504https://doi.org/10.3109/10641968709158998
        • Rolih C.A.
        • Ober K.P.
        • et al.
        The endocrine response to critical illness.
        Med Clin North Am. 1995; 79: 211-224
        • du Cheyron D.
        • Lesage A.
        • Daubin C.
        • et al.
        Hyperreninemic hypoaldosteronism: a possible etiological factor of septic shock induced acute renal failure.
        Intensive Care Med. 2003; 29 (2003): 1703-1709
        • Bucher M.
        • Hobbhahn J.
        • Kurtz A.
        • et al.
        Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis.
        Crit Care Med. 2001; 29: 1750-1755
        • Bucher M.
        • Ittner K.P.
        • Hobbhahn J.
        • et al.
        Downregulation of angiotensin II type 1 receptors during sepsis.
        Hypertension. 2001; 38: 177-182
        • Ikeda Y.
        • Takeuchi K.
        • Kato T.
        • et al.
        Transcriptional suppression of rat angiotensin AT1a receptor gene expression by interferon-gamma in vascular smooth muscle cells.
        Biochem Biophys Res Commun. 1999; 262: 494-498
        • Sasamura H.
        • Nakazato Y.
        • Hayashida T.
        • et al.
        Regulation of vascular type 1 angiotensin receptors by cytokines.
        Hypertension. 1997; 30: 35-41
        • Mederle K.
        • Schweda F.
        • Kattler V.
        • et al.
        The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension.
        Crit Care. 2013; 17: R130
      2. Correâ TD, Jeger V, Pereira AJ et al. Angiotensin II in septic shock: effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis. Crit Care Med 2014: 42(8): 550–559.doi:https://doi.org/10.1097/CCM.000000000000039.

        • Inoue N.
        • Kinugawa S.
        • Suga T.
        • et al.
        Angiotensin II-induced reduction in exercise capacity is associated with increased oxidative stress in skeletal muscle.
        Am J Physiol Heart Circ Physiol. 2012; 302: 1202-1210https://doi.org/10.1152/ajpheart.00534.2011
        • Imai Y.
        • Kuba K.
        • Rao S.
        • et al.
        Angiotensin-converting enzyme 2 protects from severe acute lung failure.
        Nature. 2005; 436: 112-116https://doi.org/10.1038/nature03712
        • Zambelli V.
        • Bellani G.
        • Borsa R.
        • et al.
        Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome.
        Intensive Care Med Exp. 2015; 3: 44https://doi.org/10.1186/s40635-015-0044-3
        • Supe S.
        • Kohse F.
        • Gembardt F.
        • et al.
        Therapeutic time window for angiotensin-(1-7) in acute lung injury.
        Br J Pharmacol. 2016; 173: 1618-1628https://doi.org/10.1111/bph.13462
        • Denton K.M.
        • Anderson W.P.
        • Sinniah R.
        • et al.
        Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole.
        Am J Physiol Regul Integr Comp Physiol. 2000; 279: 629-638
        • Wernze H.
        • Spech H.J.
        • Muller G.
        • et al.
        Studies on the activity of the renin-angiotensin-aldosterone system (RAAS) in patients with cirrhosis of the liver.
        Klin Wochenschr. 1978; 56: 389-397
      3. Zhuang S, Wang HF, Wang X et al. The association of renin angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer's disease: a meta-analysis. J Clin Neurosci 2016: 33:32–38. DOI: doi:https://doi.org/10.1016/j.jocn.2016.02.036

        • Wharton W.
        • Goldstein F.C.
        • Zhao L.
        • et al.
        Modulation of renin-angiotensin system may slow conversion from mild cognitive impairment to Alzheimer's disease.
        J Am Geriatr Soc. 2015; 63: 1749-1756https://doi.org/10.1111/jgs.13627
      4. Bali A, Jaggi AS et al. Angiotensin II-triggered kinase signaling cascade in the central nervous system. Rev Neurosci 2016: 27(3):301–315. doi: https://doi.org/10.1515/revneuro-2015-0041.

        • Villapol S.
        • Balarezo M.G.
        • Affram K.
        • et al.
        Neurorestoration after traumatic brain injury through angiotensin II receptor blockage.
        Brain. 2015; 138: 3299-3315https://doi.org/10.1093/brain/awv172
        • Busse L.W.
        • Wang X.S.
        • Chalikonda D.M.
        • et al.
        Clinical experience with IV angiotensin II administration: a systematic review of safety.
        Crit Care Med. 2017 Aug; 45: 1285-1294https://doi.org/10.1097/CCM.0000000000002441
        • Zarjou A.
        • Agarwal A.
        • et al.
        Sepsis and acute kidney injury.
        J Am Soc Nephrol. 2011; 22: 999-1006https://doi.org/10.1681/ASN.2010050484
        • Uchino S.
        • Kellum J.A.
        • Bellomo R.
        • et al.
        Acute renal failure in critically ill patients: a multinational, multicenter study.
        JAMA. 2005; 294: 813-818https://doi.org/10.1001/jama.294.7.813
        • Tumlin J.A.
        • Murugan R.
        • Deane A.M.
        • et al.
        Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II.
        Crit Care Med. 2018; 46: 949-957https://doi.org/10.1097/CCM.0000000000003092
        • Chawla L.S.
        • Eggers P.W.
        • Star R.A.
        • et al.
        Acute kidney injury and chronic kidney disease as interconnected syndromes.
        N Engl J Med. 2014; 371: 58-66https://doi.org/10.1056/NEJMra1214243
        • Joannidis M.
        • Druml W.
        • Forni L.G.
        • et al.
        Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017.
        Intensive Care Med. 2017; 43: 730-749https://doi.org/10.1007/s00134-017-4832-y
        • Gaudry S.
        • Hajage D.
        • Schortgen F.
        • et al.
        AKIKI study group: initiation strategies for renal-replacement therapy in the intensive care unit.
        N Engl J Med. 2016; 375: 122-133
        • Zarbock A.
        • Kellum J.A.
        • Schmidt C.
        • et al.
        Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial.
        JAMA. 2016; 315: 2190-2199
        • Lim H.A.
        • Lee H.H.
        • Kim A.J.
        • et al.
        Renin-angiotensin-aldosterone system blockade in critically ill patients is associated with increased risk for acute kidney injury.
        Tohoku J Exp Med. 2016; 238: 17-23 12
        • Langenberg C.
        • Bagshaw S.M.
        • May C.N.
        • et al.
        The histopathology of septic acute kidney injury: a systematic review.
        Crit Care. 2008; 12: R38https://doi.org/10.1186/cc6823
        • Schrier R.W.
        • Wang W.
        • Poole B.
        • et al.
        Acute renal failure: definitions, diagnosis, pathogenesis, and therapy.
        J Clin Invest. 2004; 114: 5-14
        • Lankadeva Y.R.
        • Kosaka J.
        • Evans R.G.
        • et al.
        Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury.
        Kidney Int. 2016; 90: 100-108
        • du Cheyron D.
        • Fradin S.
        • Ramakers M.
        • et al.
        Angiotensin converting enzyme insertion/deletion genetic polymorphism: its impact on renal function in critically ill patients.
        Crit Care Med. 2008; 36: 3178-3183
        • Orfanos S.E.
        • Armaganidis A.
        • Glynos C.
        • et al.
        Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury.
        Circulation. 2000; 102: 2011-2018
        • Khanna A.
        • English S.W.
        • Wang X.S.
        • et al.
        ATHOS-3 investigators: angiotensin II for the treatment of vasodilatory shock.
        N Engl J Med. 2017; 337: 419-430
        • Wunderink R.G.
        • Alberton T.E.
        • Busse L.W.
        • et al.
        Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II.
        Intensive Care Med Exp. 2017; 5: 0703
        • Calzavacca P.
        • Evans R.G.
        • Bailey M.
        • et al.
        Variable responses of regional renal oxygenation and perfusion to vasoactive agents in awake sheep.
        Am J Physiol Regul Integr Comp Physiol. 2015; 309: R1226-R1233
        • Lankadeva Y.R.
        • Kosaka J.
        • Evans R.G.
        • et al.
        Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury.
        Crit Care Med. 2018; 46: e41-e48
        • Brenner M.
        • Schaer G.L.
        • Mallory D.L.
        • et al.
        Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter.
        Chest. 1990; 98: 170-179
        • Wan L.
        • Langenberg C.
        • Bellomo R.
        • et al.
        Angiotensin II in experimental hyperdynamic sepsis.
        Crit Care. 2009; 13: R190
        • Prowle J.R.
        • Bellomo R.
        • et al.
        Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation.
        Semin Nephrol. 2015; 35: 64-74
        • May C.N.
        • Ishikawa K.
        • Wan L.
        • et al.
        Renal bioenergetics during early gram-negative mammalian sepsis and angiotensin II infusion.
        Intensive Care Med. 2012; 38: 886-893
        • Chawla L.S.
        • Busse L.
        • Brasha-Mitchell E.
        • et al.
        Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
        Crit Care. 2014; 18534https://doi.org/10.1186/s13054-014-0534-9
        • Khanna A.
        • English S.E.
        • Wang X.S.
        • et al.
        Angiotensin II for the treatment of vasodilatory shock.
        N Engl J Med. 2017; 377: 419-430
        • Busse L.W.
        • McCurdy M.T.
        • Ali O.
        • et al.
        The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature.
        Crit Care. 2017; 21: 324